Assembly Biosciences, Inc. Forecast, price target & analysts
Assembly Biosciences, Inc. Target price 2026 - Analyst rating & recommendation
Assembly Biosciences, Inc. Classifications & Recommendation
Assembly Biosciences, Inc. Price Target
| Target Price | $53.04 |
| Price | $22.95 |
| Potential |
131.11%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Assembly Biosciences, Inc. 2027 .
The average Assembly Biosciences, Inc. target price is $53.04.
This is
131.11%
register free of charge
$65.10
183.66%
register free of charge
$43.43
89.24%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Assembly Biosciences, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Assembly Biosciences, Inc. stock has an average upside potential 2027 of
131.11%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 72.30 | 32.21 |
| 153.51% | 55.44% | |
| EBITDA Margin | -16.58% | 105.01% |
| 89.56% | 733.21% | |
| Net Margin | -8.46% | -125.70% |
| 93.99% | 1,384.99% |
6 Analysts have issued a sales forecast Assembly Biosciences, Inc. 2026 . The average Assembly Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Assembly Biosciences, Inc. EBITDA forecast 2026. The average Assembly Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Assembly Biosciences, Inc. Analysts have issued a net profit forecast 2026. The average Assembly Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.55 | -2.04 |
| 91.78% | 270.91% | |
| P/E | negative | |
| EV/Sales | 4.56 |
Current Assembly Biosciences, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 28 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 04 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 04 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
